



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

February 22, 2021

Via E-mail

Mr. Robert J. Gould
President and Chief Executive Officer
Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, MA 02139

Re: Fulcrum Therapeutics, Inc.
Form 10-Q for the quarterly period ended September 30, 2020
Exhibit No. 10.1 Collaboration and License Agreement
Exhibit No. 10.2 First Amendment to the Right of Reference and License Agreement
Filed November 10, 2020
File No. 001-38978

Dear Mr. Gould:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance